Hematopoietic Stem Cell Transplantation in Thalassemia and Sickle Cell Anemia
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
The globally widespread single-gene disorders β-thalassemia and sickle cell anemia (SCA) can only be cured by allogeneic hematopoietic stem cell transplantation (HSCT). HSCT treatment of thalassemia has substantially improved over the last two decades, with advancements in preventive strategies, control of transplant-related complications, and preparative regimens. A risk class-based transplantation approach results in disease-free survival probabilities of 90%, 84%, and 78% for class 1, 2, and 3 thalassemia patients, respectively. Because of disease advancement, adult thalassemia patients have a higher risk for transplant-related toxicity and a 65% cure rate. Patients without matched donors could benefit from haploidentical mother-to-child transplantation. There is a high cure rate for children with SCA who receive HSCT following myeloablative conditioning protocols. Novel non-myeloablative transplantation protocols could make HSCT available to adult SCA patients who were previously excluded from allogeneic stem cell transplantation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Bone Marrow Transplantation in Patients with Thalassemia
Lucarelli, G., Galimberti, M., Polchi, P., Angelucci, E., Baronciani, D., Giardini, C., Politi, P., Durazzi, S. M. T., Muretto, P., & Albertini, F. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002153220701 · Cited by 636 · cited 1×
“The influence of pretransplant characteristics on the outcome of transplantation was analyzed in 161 patients ,17 yr of age, who were all treated with exactly the same regimen (Storb et al. 1977; Lucarelli et al. 1990).”
MethodSelf-citationLong-term results of related myeloablative stem-cell transplantation to cure sickle cell disease
Bernaudin, F., Socie, G., Kuentz, M., Chevret, S., Duval, M., Bertrand, Y., Vannier, J.-P., Yakouben, K., Thuret, I., Bordigoni, P., et al. (2007) · Blood · doi:10.1182/blood-2007-03-079665 · Cited by 515
Allogeneic Hematopoietic Stem-Cell Transplantation for Sickle Cell Disease
Hsieh, M. M., Kang, E. M., Fitzhugh, C. D., Link, M. B., Bolan, C. D., Kurlander, R., Childs, R. W., Rodgers, G. P., Powell, J. D., & Tisdale, J. F. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904971 · Cited by 455
World Distribution, Population Genetics, and Health Burden of the Hemoglobinopathies
Williams, T. N., & Weatherall, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011692 · Cited by 430
Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease
Locatelli, F. (2003) · Blood · doi:10.1182/blood-2002-07-2090 · Cited by 386 · cited 1×
“…88% Class 3: 87% Adult: 66% Class 1–2: 85% Class 3: 82% Adult: 62% Lucarelli et al. 2008 68 MUD 79.3% 40% La Nasa et al. 2005a 33 Cord blood 100% 79% Locatelli et al. 2003 70 MSD/MRD 83% 73% Ghavamzadeh et al. 1997 49 Related: 28 Unrelated: 21 89% (all patients) Related: 82% Unrelated: 71%…”
InfluentialWalters, M. C., Storb, R. F., Patience, M., Leisenring, W. M., Taylor, T., Sanders, J. E., Buchanan, G. E., Rogers, Z. R., Dinndorf, P. A., Davies, S. C., et al. (2000) · PubMed · doi:10.1182/blood.v95.6.1918 · Cited by 361
Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia
Walters, M. C., Patience, M., Leisenring, W., Rogers, Z. R., Aquino, V. M., Buchanan, G. R., Roberts, I. A. G., Yeager, A. M., Hsu, L., Adamkiewicz, T., et al. (2001) · Biology of Blood and Marrow Transplantation · doi:10.1053/bbmt.2001.v7.pm11787529 · Cited by 324 · cited 1×
“Walters et al. (2001) observed stable MC in 13 out of 50 patients (26”
BackgroundIannone, R., Casella, J. F., Fuchs, E. J., Chen, A. R., Jones, R. J., Woolfrey, A., Amylon, M., Sullivan, K. M., Storb, R. F., & Walters, M. C. (2003) · Biology of Blood and Marrow Transplantation · doi:10.1016/s1083-8791(03)00192-7 · Cited by 269 · cited 1×
“In a retrospective multicenter series, Iannone et al. (2003) described a non-myeloablative HSCT approach in six pediatric patients with SCD and one with thalassemia.”
BackgroundVermylen, C., Cornu, G., Ferster, A., Brichard, B., Ninane, J., Ferrant, A., Zenebergh, A., Maes, P., Dhooge, C., Benoit, Y., et al. (1998) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701291 · Cited by 260 · cited 1×
“The results of transplantation might be even better if HSCT were performed in children before the development of irreversible sickle vasculopathy-related complications (Vermylen et al. 1998; Lucarelli et al. 2011).”
BackgroundAPLASTIC ANAEMIA TREATED BY MARROW TRANSPLANTATION
Donnall Thomas, E., Storb, R., Fefer, A., Slichter, S., Bryant, J., Dean Buckner, C., Neiman, P., Clift, R., Funk, D., & Lerner, K. (1972) · The Lancet · doi:10.1016/s0140-6736(72)90292-9 · Cited by 250 · cited 1×
“Cyclophosphamide (CY) is a well-established agent for providing adequate immunosuppression for allogeneic engraftment (Thomas et al. 1972; Storb et al. 1991).”
BackgroundComplete Correction of the Wiskott-Aldrich Syndrome by Allogeneic Bone-Marrow Transplantation
Parkman, R., Rappeport, J., Geha, R., Belli, J., Cassady, R., Levey, R., Nathan, D. G., & Rosen, F. S. (1978) · New England Journal of Medicine · doi:10.1056/nejm197804272981701 · Cited by 250 · cited 1×
“There is a considerable body of experience with the use of busulfan (BU) and its derivatives for ablating marrow in patients undergoing HSCT for the treatment of non-malignant conditions (Parkman et al. 1978; Kapoor et al. 1981; Hobbs et al. 1986).”
BackgroundRegulation of human fetal hemoglobin: new players, new complexities
Bank, A. (2006) · Blood · doi:10.1182/blood-2005-05-2113 · Cited by 209 · cited 1×
“It is possible that after myeloablative treatment, the vast majority of committed autologous erythroid progenitors were destroyed, and only autologous hematopoietic stem cells survived in marrow niches, restoring the ontological HbF regulation mechanisms (Bank 2006).”
BackgroundAndreani, M., Nesci, S., Lucarelli, G., Tonucci, P., Rapa, S., Angelucci, E., Persini, B., Agostinelli, F., Donati, M., & Manna, M. (2000) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1702151 · Cited by 191 · cited 4×
“A subgroup of patients who undergo HSCT for SCA develop lifelong stable MC once donor– host tolerance is established (Andreani et al. 1996, 2000).”
BackgroundInfluentialSelf-citationBone Marrow Transplantation in Adult Thalassemic Patients
Lucarelli, G., Clift, R. A., Galimberti, M., Angelucci, E., Giardini, C., Baronciani, D., Polchi, P., Andreani, M., Gaziev, D., Erer, B., et al. (1999) · Blood · doi:10.1182/blood.v93.4.1164 · Cited by 182
Self-citationPanepinto, J. A., Walters, M. C., Carreras, J., Marsh, J., Bredeson, C. N., Gale, R. P., Hale, G. A., Horan, J., Hows, J. M., Klein, J. P., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06592.x · Cited by 179
The cure of thalassemia by bone marrow transplantation
Lucarelli, G., Andreani, M., & Angelucci, E. (2002) · Blood Reviews · doi:10.1054/blre.2002.0192 · Cited by 175 · cited 2×
“The incidence of MC was evaluated in 335 patients who received BMT from HLA-matched family donors for thalassemia; it was found to be 32.2% at 2 mo after transplant (Lucarelli et al. 2002).”
BackgroundInfluentialSelf-citationPersistence of mixed chimerism in patients transplanted for the treatment of thalassemia
Andreani, M., Manna, M., Lucarelli, G., Tonucci, P., Agostinelli, F., Ripalti, M., Rapa, S., Talevi, N., Galimberti, M., & Nesci, S. (1996) · Blood · doi:10.1182/blood.v87.8.3494.bloodjournal8783494 · Cited by 168 · cited 5×
“1998; Andreani et al. 2000). Thus, myeloablation may not be necessary for a successful outcome. In a retrospective multicenter series, Iannone et al. (2003) described a non-myeloablative HSCT approach in six pediatric patients with SCD and one with thalassemia.”
BackgroundInfluentialSelf-citationAdvances in the allogeneic transplantation for thalassemia
Lucarelli, G., & Gaziev, J. (2008) · Blood Reviews · doi:10.1016/j.blre.2007.10.001 · Cited by 162
Self-citationAllogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now
Hsieh, M. M., Fitzhugh, C. D., & Tisdale, J. F. (2011) · Blood · doi:10.1182/blood-2011-01-332510 · Cited by 152 · cited 1×
“The experience of cord blood transplantation (CBT) has been limited in patients with SCD, with a total of 33 cases reported, twothirds of whom were in the related donor setting (Hsieh et al. 2011).”
BackgroundLA NASA, G., ARGIOLU, F., GIARDINI, C., PESSION, A., FAGIOLI, F., CAOCCI, G., VACCA, A., DE STEFANO, P., PIRAS, E., LEDDA, A., et al. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1345.023 · Cited by 147 · cited 3×
“These investigators have also recently reported encouraging results inadult thalassemia patients who received bone marrow from matched unrelated donors, with rates of survival, thalassemia-free survival, TRM, and rejection of 70%, 70%, 30%, and 4%, respectively (La Nasa et al. 2005b).”
MethodResultInfluentialHLA-matched sibling bone marrow transplantation for β-thalassemia major
Sabloff, M., Chandy, M., Wang, Z., Logan, B. R., Ghavamzadeh, A., Li, C.-K., Irfan, S. M., Bredeson, C. N., Cowan, M. J., Gale, R. P., et al. (2011) · Blood · doi:10.1182/blood-2010-09-306829 · Cited by 133 · cited 4×
“%) developed chronic GVHD. Class 1 and class 2 patients had much better overall and disease-free survival (96.7% and 80%, respectively) than class 3 patients (65.5% and 54.5%, respectively).”
InfluentialKrishnamurti, L., Kharbanda, S., Biernacki, M. A., Zhang, W., Baker, K. S., Wagner, J. E., & Wu, C. J. (2008) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2008.08.016 · Cited by 129 · cited 1×
“In a recent study, seven patients (18 yr or younger) with high-risk SCD were given a bone marrow graft from an HLA-matched sibling donor (Krishnamurti et al. 2008).”
BackgroundAndreani, M., Testi, M., Gaziev, J., Condello, R., Bontadini, A., Tazzari, P. L., Ricci, F., De Felice, L., Agostini, F., Fraboni, D., et al. (2011) · Haematologica · doi:10.3324/haematol.2010.031013 · Cited by 106 · cited 3×
“We recently published a paper describing four long-term transplanted patients affected by hemoglobinopathies (Andreani et al. 2011a).”
BackgroundSelf-citationSodani, P., Isgrò, A., Gaziev, J., Polchi, P., Paciaroni, K., Marziali, M., Simone, M. D., Roveda, A., Montuoro, A., Alfieri, C., et al. (2009) · Blood · doi:10.1182/blood-2009-05-218982 · Cited by 104 · cited 1×
“All of the 22 cured children are no longer transfusion-dependent, with hemoglobin levels ranging from 10.3 g/dL to 13.8 g/dL (Sodani et al. 2010, 2011).”
BackgroundInfluentialSelf-citationBone Marrow Transplantation in Adults with Thalassemia: Treatment and Long‐Term Follow‐Up
GAZIEV, J., SODANI, P., POLCHI, P., ANDREANI, M., & LUCARELLI, G. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1345.024 · Cited by 100 · cited 1×
“The probabilities of survival, thalassemia-free survival, rejection mortality, and non-rejection mortality were 65%, 65%, 7%, and 28%, respectively (Gaziev et al. 2005).”
BackgroundSelf-citationFludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease
van Besien, K., Bartholomew, A. M., Stock, W., Peace, D. J., Devine, S. M., Sher, D., Sosman, J. A., Chen, Y.-H., Koshy, M., & Hoffman, R. (2000) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1702518 · Cited by 97
Kapoor, N., Kirkpatrick, D. V., Blaese, R. M., Oleske, J. M., Hilgartner, M. W., CHAGANTI, R. S. K., Ra, G., & O’Reilly, R. (1981) · Blood · doi:10.1182/blood.v57.4.692.bloodjournal574692 · Cited by 90
Bone marrow transplantation in sickle cell anemia
Hoppe, C. C., & Walters, M. C. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200103000-00001 · Cited by 79
Unrelated donor stem cell transplantation in adult patients with thalassemia
Nasa, G. L., Caocci, G., Argiolu, F., Giardini, C., Locatelli, F., Vacca, A., Orofino, M. G., Piras, E., Addari, M. C., Ledda, A., et al. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705173 · Cited by 75 · cited 3×
“These investigators have also recently reported encouraging results inadult thalassemia patients who received bone marrow from matched unrelated donors, with rates of survival, thalassemia-free survival, TRM, and rejection of 70%, 70%, 30%, and 4%, respectively (La Nasa et al. 2005b).”
MethodResultInfluentialBone marrow transplantation in adult thalassemia
Lucarelli, G. T., GALIMBERTI, M., Polchi, P., Angelucci, E., BARONCIANI, D., Durazzi, S. M. T., Giardini, C., Albertini, F., & Clift, R. A. (1992) · Blood · doi:10.1182/blood.v80.6.1603.1603 · Cited by 74
Self-citationAdamkiewicz, T. V., Szabolcs, P., Haight, A. E., Baker, K. S., Staba, S. L., Kedar, A., Chiang, K. Y., Krishnamurti, L., Boyer, M. W., Kurtzberg, J., et al. (2007) · Pediatric Transplantation · doi:10.1111/j.1399-3046.2007.00725.x · Cited by 70 · cited 1×
“The largest study consisting of seven patients reported one death, an EFS of 43%, five patients developed acute GVHD, and one patient chronic GVHD (Adamkiewicz et al. 2007).”
BackgroundHEMOPOIETIC GRAFTS BETWEEN DLA-IDENTICAL CANINE LITTERMATES FOLLOWING DIMETHYL MYLERAN
Storb, R. F., WEIDEN, P. L., GRAHAM, T. C., Lerner, K. G., Nelson, N., & Thomas, E. D. (1977) · Transplantation · doi:10.1097/00007890-197711000-00006 · Cited by 63
Hongeng, S., Pakakasama, S., Chuansumrit, A., Sirachainan, N., Kitpoka, P., Udomsubpayakul, U., Ungkanont, A., & Jootar, S. (2006) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2006.02.008 · Cited by 62 · cited 2×
“Similar results were reported in another study from Asia that included 21 children who received transplants from matched unrelated donors, as well as 28 patients who received transplants from matched related donors (Hongeng et al. 2006).”
ResultHobbs, J. R., Hugh-Jones, K., Shaw, P. J., Downie, C. J., & Williamson, S. (1986) · PubMed · Cited by 58
T Cell-Depleted HlA-Haploidentical Stem Cell Transplantation in Thalassemia Young Patients
Sodani, P., Isgrò, A., Gaziev, J., Paciaroni, K., Marziali, M., Simone, M. D., Roveda, A., Alfieri, C., Angelis, G. D., Gallucci, C., et al. (2011) · Pediatric Reports · doi:10.4081/pr.2011.s2.e13 · Cited by 49 · cited 3×
“…stem cells, and T-cells) to a T-celldepleted allograft may help engraftment and control GVHD. Recently, we reported the outcomes of 31 children with thalassemia who received transplants from haploidentical donors; 27 were from mothers, two from brothers, and two from fathers (Sodani et al. 2011).”
BackgroundInfluentialSelf-citationBone marrow transplantation for severe aplastic anemia.
Storb, R. F., & Champlin, R. E. (1991) · PubMed · Cited by 48
BONE MARROW TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA
Champlin, R. E., Ho, W. G., Nimer, S. D., Gajewski, J., Selch, M. T., Burnison, M., Holley, G. U., Yam, P. Y., Petz, L. D., Winston, D. J., et al. (1990) · Transplantation · doi:10.1097/00007890-199004000-00013 · Cited by 47
Isgrò, A., Gaziev, J., Sodani, P., & Lucarelli, G. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05543.x · Cited by 46 · cited 3×
“The results of transplants from HLA-matched related donors to class 1, class 2, and class 3 patients, obtained by our group, are reported in Table 1 (Lucarelli et al. 2008; Isgrò et al. 2010).”
BackgroundInfluentialSelf-citationLucarelli, G. T., Gaziev, J., Isgrò, A., Sodani, P., Paciaroni, K., Alfieri, C., Angelis, G. D., Marziali, M., Simone, M. D., Gallucci, C., et al. (2011) · Bone Marrow Transplantation · doi:10.1038/bmt.2011.79 · Cited by 41 · cited 4×
“The results of transplantation might be even better if HSCT were performed in children before the development of irreversible sickle vasculopathy-related complications (Vermylen et al. 1998; Lucarelli et al. 2011).”
BackgroundInfluentialSelf-citationFERSTER, A., CORAZZA, F., VERTONGEN, F., BUJAN, W., DEVALCK, C., FONDU, P., COCHAUX, P., LAMBERMONT, M., KHALADJI, Z., & SARIBAN, E. (1995) · British Journal of Haematology · doi:10.1111/j.1365-2141.1995.tb05199.x · Cited by 36
Bone marrow transplantation in sickle cell anaemia.
Vermylen, C., Cornu, G., Philippe, M., Ninane, J., Borja, A., Latinne, D., Ferrant, A., Michaux, J., & SOKAL, G. (1991) · Archives of Disease in Childhood · doi:10.1136/adc.66.10.1195 · Cited by 35
The Cure of the Thalassemia with Bone Marrow Transplantation
Lucarelli, G. T., Andreani, M., & Angelucci, E. (2001) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1703169 · Cited by 31
Self-citationAndreani, M., Testi, M., Battarra, M., & Lucarelli, G. (2011) · Chimerism · doi:10.4161/chim.15057 · Cited by 29 · cited 3×
“We recently published a paper describing four long-term transplanted patients affected by hemoglobinopathies (Andreani et al. 2011a).”
BackgroundSelf-citationAndreani, M., Testi, M., Battarra, M., et al. (2011) · PubMed · doi:10.4161/chim.2.1.15057 · Cited by 24
Prognostic factors in bone marrow transplantation for beta thalassemia major: experiences from Iran
Ghavamzadeh, A., Nasseri, P., Eshraghian, M., Jahani, M., Baybordi, I., Nateghi, J., Khodabandeh, A., Sadjadi, A., Mohyeddin, M., & Khademi, Y. (1998) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701509 · Cited by 23 · cited 1×
“…85% Class 3: 82% Adult: 62% Lucarelli et al. 2008 68 MUD 79.3% 40% La Nasa et al. 2005a 33 Cord blood 100% 79% Locatelli et al. 2003 70 MSD/MRD 83% 73% Ghavamzadeh et al. 1997 49 Related: 28 Unrelated: 21 89% (all patients) Related: 82% Unrelated: 71% Hongeng et al. 2006 37 (class 1–2) 35 (class…”
InfluentialBone marrow transplantation in sickle-cell anemia in Pesaro.
Giardini, C., GALIMBERTI, M., Lucarelli, G. T., Polchi, P., Angelucci, E., BARONCIANI, D., Agostinelli, F., Giorgi, C., & Muretto, P. (1993) · PubMed · Cited by 21
Self-citationBone marrow transplantation in sickle cell anaemia
Vermylen, C., & Cornu, G. (1993) · Blood Reviews · doi:10.1016/0268-960x(93)90017-x · Cited by 18
Bone Marrow Transplantation in Adult Thalassemic Patients
Lucarelli, G. T., Clift, R., GALIMBERTI, M., et al. (1999) · Blood · doi:10.1182/blood.v93.4.1164.404k18_1164_1167 · Cited by 16 · cited 1×
“The probabilities of survival, thalassemia-free survival, rejection mortality, and non-rejection mortality for this entire group were 66%, 62%, 4%, and 37%, respectively (Lucarelli et al. 1992, 1999).”
BackgroundSelf-citationBone marrow transplantation for sickle cell anemia
Vermylen, C., Cornu, G., Ferster, A., & Sariban, E. (1994) · The Journal of Pediatrics · doi:10.1016/s0022-3476(94)70331-0 · Cited by 14
Mixed Chimerism after Bone Marrow Transplantation in Thalassemia
Nesci, S., Manna, M., Lucarelli, G. T., Tonucci, P., DONATI, M., Buffi, O., Agostinelli, F., & Andreani, M. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb10531.x · Cited by 14 · cited 1×
“The rationale for lower-intensity conditioning regimens in hemoglobinopathies stems from historical experience indicating that stable MC is sufficient for cure (Nesci et al. 1998; Andreani et al. 2000).”
BackgroundSelf-citationBone marrow transplantation in adult thalassemia
Lucarelli, G. T., GALIMBERTI, M., Polchi, P., et al. (1992) · Blood · doi:10.1182/blood.v80.6.1603.bloodjournal8061603 · Cited by 13 · cited 1×
“The probabilities of survival, thalassemia-free survival, rejection mortality, and non-rejection mortality for this entire group were 66%, 62%, 4%, and 37%, respectively (Lucarelli et al. 1992, 1999).”
BackgroundSelf-citationPaciaroni, K., Gallucci, C., Angelis, G. D., Alfieri, C., Roveda, A., & Lucarelli, G. (2009) · American Journal of Hematology · doi:10.1002/ajh.21392 · Cited by 11
Self-citation
Cited by
Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia
Thompson, A. A., Walters, M. C., Kwiatkowski, J., Rasko, J. E. J., Ribeil, J.-A., Hongeng, S., Magrin, E., Schiller, G. J., Payen, E., Semeraro, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705342 · Cited by 684
Snowden, J. A., Sánchez-Ortega, I., Corbacioglu, S., Basak, G. W., Chabannon, C., de la Camara, R., Dolstra, H., Duarte, R. F., Glass, B., Greco, R., et al. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-022-01691-w · Cited by 379
Sureda, A., Bader, P., Cesaro, S., Dreger, P., Duarte, R. F., Dufour, C., Falkenburg, J. H. F., Farge-Bancel, D., Gennery, A., Kröger, N., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.6 · Cited by 337
for the European Society for Blood and Marrow Transplantation (EBMT), Duarte, R. F., Labopin, M., Bader, P., Basak, G. W., Bonini, C., Chabannon, C., Corbacioglu, S., Dreger, P., Dufour, C., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0516-2 · Cited by 337
A phase 3 trial of luspatercept in patients with transfusion-dependent β-thalassemia.
Cappellini, M. D., Viprakasit, V., Taher, A. T., Georgiev, P., Kuo, K. H. M., Coates, T., Voskaridou, E., Liew, H.-K., Pazgal-Kobrowski, I., Forni, G. L., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910182 · Cited by 332
Metadata
- Authors
- Lucarelli, G., Isgro, A., Sodani, P., & Gaziev, J.
- Affiliations
- University of Rome Tor Vergata (IT)
- Corresponding author
- Lucarelli, G.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2012-04-04
- Volume
- 2
- Issue
- 5
- Pages
- a011825-a011825
- ISSN
- 2157-1422 (ISSN-L)
- PMC
- PMC3331690
- OpenAlex
- W2113456470
- Cited by
- 166
- References
- 50
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 14 · 2023: 16 · 2022: 12 · 2021: 14 · 2020: 14 · 2019: 12 · 2018: 10 · 2017: 11 · 2016: 12 · 2015: 10 · 2014: 16 · 2013: 6 · 2012: 2
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Hematology › Blood transfusion and management
- Keywords
- hematopoietic stem cell transplantation, thalassemia, sickle cell disease, allogeneic transplantation, risk stratification, transplant toxicity, haploidentical transplantation, myeloablative conditioning, nonmyeloablative conditioning, disease-free survival
- MeSH terms
- Adult, Anemia, Sickle Cell, Graft vs Host Disease, Humans, Thalassemia, Hematopoietic Stem Cell Transplantation, Living Donors, Myeloablative Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.